Authors: DILLMAN RO WIEMANN MC VANDERMOLEN LA BURY MJ DEPRIEST C CHURCH C

Citation: Ro. Dillman et al., HYBRID HIGH-DOSE BOLUS CONTINUOUS-INFUSION INTERLEUKIN-2 IN PATIENTS WITH METASTATIC MELANOMA - A PHASE-II TRIAL OF THE CANCER-BIOTHERAPY-RESEARCH-GROUP (FORMERLY THE NATIONAL-BIOTHERAPY-STUDY-GROUP), CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(4), 1997, pp. 249-255

Authors: DILLMAN RO BARTH NM VANDERMOLEN LA MAHDAVI K NAYAK SK

Citation: Ro. Dillman et al., HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL RESCUE IN HEMATOLOGICMALIGNANCIES - SINGLE INSTITUTION EXPERIENCE, Blood, 90(10), 1997, pp. 4553-4553

Authors: GAUSE BL SZNOL M KOPP WC JANIK JE SMITH JW STEIS RG URBA WJ SHARFMAN W FENTON RG CREEKMORE SP HOLMLUND J CONLON KC VANDERMOLEN LA LONGO DL

Citation: Bl. Gause et al., PHASE-I STUDY OF SUBCUTANEOUSLY ADMINISTERED INTERLEUKIN-2 IN COMBINATION WITH INTERFERON ALFA-2A IN PATIENTS WITH ADVANCED CANCER, Journal of clinical oncology, 14(8), 1996, pp. 2234-2241

Authors: DILLMAN RO VANDERMOLEN LA BARTH NM BRANSFORD KJ

Citation: Ro. Dillman et al., MALIGNANT-MELANOMA AND PREGNANCY - 10 QUESTIONS, Western journal of medicine, 164(2), 1996, pp. 156-161

Authors: DILLMAN RO BARTH NM VANDERMOLEN LA MAHDAVI K NAYAK SK

Citation: Ro. Dillman et al., SINGLE INSTITUTION EXPERIENCE WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL RESCUE IN HEMATOLOGIC MALIGNANCIES - 1990-1996, Blood, 88(10), 1996, pp. 3856-3856

Authors: DILLMAN RO BARTH NM MAHDAVI K VANDERMOLEN LA NAYAK SK OCONNOR A

Citation: Ro. Dillman et al., THE INTEGRATION OF HIGH-DOSE CHEMOTHERAPY AND BIOTHERAPY - INITIAL 5-YEAR EXPERIENCE WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN A COMPREHENSIVE COMMUNITY CANCER CENTER, Cancer biotherapy, 10(1), 1995, pp. 25-36